Bruno Medeiros

Hematologist, Medical oncologist

Associate Professor of Medicine (Hematology) at the Stanford University Medical Center

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: University of Colorado Health Science Center (2005) CO

Fellowship, Acute leukemia, Princess Margaret Hospital - University of Toronto (2006)

Board Certification: Hematology, American Board of Internal Medicine (2006)

Board Certification: Medical Oncology, American Board of Internal Medicine (2005)

Residency: University of Colorado Health Science Center (2002) CO

Internship: University of Connecticut Health Center (2000) CT

Medical Education: University Federal Do Parana (1998) Brazil

Administrative Appointments

Director, Stanford Hospital Hematology Inpatient service (2011 - 2014)

Director, Stanford Acute Leukemia Clinical Research Program (2009 - 2014)

Panel member adult oncology committee, National comprehensive cancer network (2010 - 2014)

Acute Leukemia Panel Member, Southwest Oncology Group (SWOG) (2007 - 2014)

Panel Member Multiple Myeloma Committee, National Comprehensive Cancer Network (2007 - 2011)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014). Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 111(7), 2548-2553.

Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia
Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., & Appelbaum, F. R. (2014). Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 164(2), 245-250.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., & Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. HAEMATOLOGICA, 98(4), 591-596.

Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia
Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., & Appelbaum, F. R. (2012). Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(9), 1401-1404.

Blood consult: monosomal karyotype acute myeloid leukemia
Garcia, J. S., Medeiros, B. C., & Appelbaum, F. R. (2012). Blood consult: monosomal karyotype acute myeloid leukemia. BLOOD, 119(24), 5659-5660.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., & Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893-901.

Impact of residual normal metaphases in core binding factor acute myeloid leukemia
Medeiros, B. C., Othus, M., Fang, M., Appelbaum, F. R., & Estey, E. H. (2012). Impact of residual normal metaphases in core binding factor acute myeloid leukemia. CANCER, 118(9), 2420-2423.

Unveiling the complexity of CK+ AML.
Medeiros, B. C. (2012). Unveiling the complexity of CK+ AML. Blood, 119(9), 1958-1959.

Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45-50.

Cytarabine Dose for Acute Myeloid Leukemia
Medeiros, B. C., Othus, M., & Appelbaum, F. R. (2011). Cytarabine Dose for Acute Myeloid Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 364(22), 2167-2168.

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience
Medeiros, B. C., Othus, M., Fang, M., Roulston, D., & Appelbaum, F. R. (2010). Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. BLOOD, 116(13), 2224-2228.

Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia
Pierceall, W. E., Lena, R. J., Medeiros, B. C., Blake, N., Doykan, C., & Walter, R. B. (2014). Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. LEUKEMIA RESEARCH, 38(5), 564-568.

Senior Adult Oncology, Version 2.2014
Hurria, A., Wildes, T., Blair, S. L., Browner, I. S., Cohen, H. J., & Sundar, H. (2014). Senior Adult Oncology, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(1), 82-126.

Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia.
Medeiros, B. C. (2014). Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia. Acta haematologica, 131(4), 200-201.

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
Walter, R. B., Medeiros, B. C., Gardner, K. M., Orlowski, K. F., Gallegos, L., & Estey, E. H. (2014). Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. HAEMATOLOGICA, 99(1), 54-59.

Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic
Wildes, T. M., Stirewalt, D. L., Medeiros, B., & Hurria, A. (2014). Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(1), 128-136.

Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes.
Jagsi, R., Chiang, A., Polite, B. N., Medeiros, B. C., McNiff, K., & Loehrer, P. J. (2013). Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes. Journal of oncology practice / American Society of Clinical Oncology, 9(6), e290-7.

A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia
Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 54(10), 2231-2235.

CD11b expression and MK+ AML: A sign of impending doom?
Medeiros, B. C. (2013). CD11b expression and MK+ AML: A sign of impending doom?. LEUKEMIA RESEARCH, 37(2), 121-121.

2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels
Pollyea, D. A., Kohrt, H. E., Zhang, B., Zehnder, J., Schenkein, D., & Medeiros, B. C. (2013). 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. LEUKEMIA & LYMPHOMA, 54(2), 408-410.

CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells
Kim, D., Park, C. Y., Medeiros, B. C., & Weissman, I. L. (2012). CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells. LEUKEMIA, 26(12), 2530-2537.

Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
Becker, P. S., Medeiros, B. C., Stein, A. S., Appelbaum, F. R., Scott, B. L., & Estey, E. H. (2012). Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. BLOOD, 120(21).

A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21).

Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options. HEMATOLOGY, 17(6), 325-328.

Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., & Shead, D. A. (2012). Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(10), 1211-1219.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., & Shead, D. A. (2012). Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. Journal of the National Comprehensive Cancer Network , 10(10), 1211-1219.

Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., & Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957-960.

Novel agents in acute myeloid leukemia
Ungewickell, A., & Medeiros, B. C. (2012). Novel agents in acute myeloid leukemia. INTERNATIONAL JOURNAL OF HEMATOLOGY, 96(2), 178-185.

New treatment approaches for older adults with multiple myeloma
Wildes, T. M., Vij, R., Petersdorf, S. H., Medeiros, B. C., & Hurria, A. (2012). New treatment approaches for older adults with multiple myeloma. JOURNAL OF GERIATRIC ONCOLOGY, 3(3), 279-290.

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
Walter, R. B., Medeiros, B. C., Powell, B. L., Schiffer, C. A., Appelbaum, F. R., & Estey, E. H. (2012). Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(5), 739-742.

Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma?
Batra, R., Medeiros, B. C., Zehnder, J. L., Warnke, R. A., & Natkunam, Y. (2012). Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma?. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(3), 325-330.

Senior Adult Oncology
Hurria, A., Browner, I. S., Cohen, H. J., Denlinger, C. S., deShazo, M., & Wildes, T. (2012). Senior Adult Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(2), 162-209.

"It doesn't matter if you're black or white", does it?
Medeiros, B. C. (2012). "It doesn't matter if you're black or white", does it?. LEUKEMIA RESEARCH, 36(2), 127-127.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., & Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30-37.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133-136.

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
Becker, P. S., Medeiros, B. C., Appelbaum, F. R., Scott, B. L., Hendrie, P. C., & Estey, E. H. (2011). Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. BLOOD, 118(21), 1545-1545.

Multiple Myeloma
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., & Yunus, F. (2011). Multiple Myeloma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(10), 1146-1183.

Unfavorable-risk cytogenetics in acute myeloid leukemia
Hong, W.-J., & Medeiros, B. C. (2011). Unfavorable-risk cytogenetics in acute myeloid leukemia. EXPERT REVIEW OF HEMATOLOGY, 4(2), 173-184.

Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer
Wang, M., Medeiros, B. C., Erba, H. P., DeAngelo, D. J., Giles, F. J., & Swords, R. T. (2011). Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. EXPERT OPINION ON THERAPEUTIC TARGETS, 15(3), 253-264.

Acute myeloid leukaemia in the elderly: a review
Pollyea, D. A., Kohrt, H. E., & Medeiros, B. C. (2011). Acute myeloid leukaemia in the elderly: a review. BRITISH JOURNAL OF HAEMATOLOGY, 152(5), 524-542.

Microfluidic purification and analysis of hematopoietic stem cells from bone marrow
Schirhagl, R., Fuereder, I., Hall, E. W., Medeiros, B. C., & Zare, R. N. (2011). Microfluidic purification and analysis of hematopoietic stem cells from bone marrow. LAB ON A CHIP, 11(18), 3130-3135.

A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., & Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347-1347.

Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., & Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357-1358.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.

Plasma cell leukemia: concepts and management.
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert review of hematology, 3(5), 543-549.

Plasma cell leukemia: concepts and management
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. EXPERT REVIEW OF HEMATOLOGY, 3(5), 539-549.

Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge
Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., & George, T. I. (2010). Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. AMERICAN JOURNAL OF HEMATOLOGY, 85(8), 600-606.

PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)
Walter, B., Medeiros, B., Nielsen-Stoeck, M., Harrington, E., Powell, B., & Estey, E. (2010). PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML). HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 29-30.

Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., & Alizadeh, A. A. (2010). Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). LEUKEMIA RESEARCH, 34(5), 594-597.

Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420-421.

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., & Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646-647.

Multiple Myeloma
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, S., Chanan-Khan, A., & Yunus, F. (2009). Multiple Myeloma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 7(9), 908-942.

Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy
Pretz, J., & Medeiros, B. C. (2009). Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. AMERICAN JOURNAL OF HEMATOLOGY, 84(10), 698-699.

NCCN clinical practice guidelines in oncology: multiple myeloma.
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., & Yunus, F. (2009). NCCN clinical practice guidelines in oncology: multiple myeloma. Journal of the National Comprehensive Cancer Network , 7(9), 908-942.

Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., & Zehnder, J. (2009). Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Medeiros, B. C. (2009). Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 360(17), 1787-1787.

Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia
Medeiros, B. C. (2009). Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(12), 2105-2105.

Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia
Medeiros, B. C. (2009). Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(3), 474-474.

Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study
McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., & George, T. I. (2009). Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study. LABORATORY INVESTIGATION, 89, 277A-277A.

Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.
Chan, S. M., George, T., Cherry, A. M., & Medeiros, B. C. (2009). Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Cases journal, 2(1), 121-?.